Acute kidney injury (AKI) after liver transplantation (LT) is a common event, but its pathogenesis remains unclear. The aim of this prospective study is to investigate the potential relationship between postreperfusion gene expression, serum mediators, and the onset of AKI after LT. Sixty-five consecutive patients undergoing LT were included in the study. Reverse transcription polymerase chain reaction (PCR) was performed on liver biopsies. Gene expression of 23 genes involved in ischemia/reperfusion injury (IRI) was evaluated. The serum concentrations of endothelin (ET)-1 and inflammatory cytokines were analyzed. AKI after LT developed in 21 (32%) recipients (AKI group). Reverse transcription PCR of reperfusion biopsy in the AKI group showed higher expression of several genes involved in IRI compared with the non-AKI group. Fold changes in the gene expression of ET-1, interleukin (IL) 18, and tumor necrosis factor a (TNF-a) were associated with creatinine peak value. AKI patients also had significantly higher ET-1, IL18, and TNF-a postoperative serum levels. Multivariate analysis showed that ET-1 (odds ratio [OR], 16.7; 95% confidence interval [CI], 3.34-83.42; P 5 0.001) and IL18 (OR, 5.27; 95% CI, 0.99-27.82, P 5 0.048) serum levels on postoperative day 1 were independently predictive of AKI. Receiver operating characteristic analysis demonstrated that the combination of biomarkers ET-11IL18 was highly predictive of AKI (area under the receiver operating characteristic curve, 0.91; 95% CI, 0.83-0.99). Early allograft dysfunction and chronic kidney disease stage 2 occurred more frequently in AKI patients. These results suggest that the graft itself, rather than intraoperative hemodynamic instability, plays a main role in AKI after LT. These data may have mechanistic and diagnostic implications for AKI after LT.
Acute kidney injury (AKI) is a well-recognized problem after liver transplantation (LT) and is associated with significant morbidity and mortality.
(1) AKI after LT is also known to be a risk factor for the development of chronic renal failure, which is associated with inferior longterm survival. (2) Understanding the factors that cause AKI early after LT is fundamental for early diagnosis and the development of new therapeutic approaches that may improve outcomes. Although AKI after LT is common, its pathogenesis remains unclear. Previous experimental studies have demonstrated a correlation between hepatic ischemia/reperfusion injury (IRI) and histological evidence of kidney injury. (3) More recently, several clinical studies demonstrated that early allograft dysfunction (EAD), which is mainly due to IRI, is associated with AKI after LT. (2, 4) Although it has been hypothesized that the AKI after LT is a direct effect of the circulating mediators released by the ischemia/reperfusion milieu, (5, 6) the link between the hepatic postreperfusion inflammatory response and AKI after LT remains poorly defined. Serum mediators released following IRI can be regarded as an intermediate and potentially modifiable factor. These early mediators can be used to identify patients at risk of AKI who may benefit from early intervention such as the use of selective antagonists. The aim of this prospective study is to investigate the potential relationship between postreperfusion gene expression, serum mediators, and the onset of AKI after LT.
Patients and Methods
From May 2013 to June 2014, 65 patients receiving full-size liver transplants were included in this study. Patients receiving split-graft, multiorgan transplantation or requiring preoperative renal replacement therapy (RRT) were excluded from the study. All patients underwent LT without using a venovenous bypass.
Our institutional ethics committee approved the study. All patients signed an informed consent.
OUTCOME ASSESSMENT
Early onset AKI (first week after LT) was defined according to the most recent International Club of Ascites-Acute Kidney Injury (ICA-AKI) guidelines as a rise in serum creatinine 50% from baseline or a rise in serum creatinine 26.5 mmol/L (0.3 mg/dL) in <48 hours. (7) Kidney function was measured using the estimated glomerular filtration rate (eGFR) calculated by the 4-variable Modification of Diet in Renal Disease study equation and serial serum creatinine. Baseline serum creatinine was defined as the creatinine value at the day of LT. Chronic kidney disease (CKD) was defined according to the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation. (8) EAD was defined as the presence of 1 or more of the following: bilirubin 10 mg/dL on day 7, international normalized ratio 1.6 on day 7, or alanine aminotransferase (ALT) >2000 IU/L within the first 7 days. (9) The histopathological grading of donor liver steatosis was performed on the postreperfusion biopsy performed during the transplant procedure. Posttransplant immunosuppression was achieved using intravenous methylprednisolone followed by oral prednisone, tacrolimus, and mycophenolate mofetil. In hepatitis C virus (HCV)-positive patients, a steroid-free protocol was used. Patient with preoperative renal dysfunction or evidence of renal impairment immediately after LT received induction treatment with basiliximab (days 1 and 5). The mean tacrolimus trough levels of the entire cohort on postoperative days (PODs) 2, 5, and 7 were 5.2 (standard deviation [SD], 4.2) lg/L, 7.1 (SD, 5.1) lg/L, and 8.5 (SD, 4.2) lg/L, respectively. During transplant, recipient hemodynamics were monitored using a pulmonary artery and intra-arterial catheter.
GENE EXPRESSION
Wedge biopsies were taken from the liver after storage and again approximately 90 minutes after reperfusion. All biopsies were promptly snap-frozen and transferred to 2808C storage until the time of processing. Total RNA from liver biopsies was isolated with Trizol reagent (Invitrogen, Life Technologies, Carlsbad, CA), and complementary DNA (cDNA) was synthesized using SuperScript III Reverse Transcriptase (Life Technologies, Carlsbad, CA). Customized TaqMan Array Microfluidic Card were designed using the assays validated by the NOTE: Data are presented as mean 6 SD or n (%) where appropriate, unless otherwise noted.
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Peripheral venous blood samples were collected preoperatively, 30 minutes after liver reperfusion, and on PODs 1, 2, 5, and 7. Samples were immediately centrifuged and stored at 2808C until assay. The serum concentrations of endothelin-1 (ET-1), tumor necrosis alpha (TNF-a), interleukin-6 (IL-6), interleukin-18 (IL-18), and RANTES were analyzed with Luminex multiplex bead immunoassay technology. The fluorescent multiplex beads for this study were obtained from R&D (Minneapolis, MN). The assay was performed according to the manufacturer's instructions with the Luminex 200 system (Luminex Corp., Austin, TX). Standard curves for each cytokine were generated by using the reference cytokine concentrations supplied by the manufacturer.
STATISTICS
Data are reported as mean 6 SD. A Student t test (2-sided, equal variances, unpaired) was used when the results were normally distributed, and the MannWhitney U test was used otherwise. The associations between gene expression (expressed as a ratio) or serum mediators and clinical data were performed with Spearman's test. A univariate analysis was used to identify variables associated with AKI. Significant variables in the univariate analysis (P 0.1) were included in a multivariate logistic regression model to identify independent predictors of AKI. Receiver operating characteristic (ROC) curve was used to create cutoff values to determine the prognostic value of serum markers with regard to the development of AKI. A combination model was evaluated to examine how a combination of biomarkers could improve the ability to predict AKI. Differences in the gene expression between the 2 groups were evaluated by a paired t test. The Bonferroni procedure for multiple testing was applied. To detect the predictive association between gene expression and development of AKI, we used the prediction method of k-nearest neighbors (k, 1 and 3; random permutations, 1000) in genes significantly different between the classes at the 0.05 significance level. All analyses were performed using the statistical package SPSS, version 18.0 (SPSS, Chicago, IL) and GraphPad Prism Software, version 6.0 (GraphPad Software, La Jolla, CA). 
ASSOCIATION BETWEEN THE GENE EXPRESSION AND CLINICAL DATA
Up-regulation of several studied genes occurred after reperfusion. The change in gene expression in postreperfusion biopsies was compared between the AKI group and the non-AKI group ( Table 2 ). The expression of several genes involved in inflammatory response, apoptosis, adhesions, and ET-1 in the AKI group was significantly greater in comparison with the non-AKI group. Associations between gene expression and clinical data were evaluated. In the AKI group, large fold changes in the expression of ET-1 were associated with peak postoperative creatinine (r, 0.710; P 5 0.001) and ALT peak (r, 0.680; P 5 0.001). Similarly, peak postoperative creatinine had a significant correlation with expression of IL18 (r, 0.653; P 5 0.01) and TNF-a (r, 0.648; P 5 0.01). Regarding donor variables, ET-1 was positively correlated with the use of inotropes in the donors (r, 0.480; P 5 0.02) and with hepatic steatosis (r, 0.521; P 5 0.01). In the non-AKI group, none of the biochemical indices or donor factors showed any correlation with gene expression. We assessed the predictive association between gene expression and outcome using the k-nearest neighbors analysis. Ten genes differentially expressed between AKI and non-AKI were considered (ET-1, IL18, CX3CL1, IL1B, IL6, TNF, BCL2L1, CASP1, SOD1, and HO-1). The nearest neighbor classifier allowed a correct classification regarding AKI in 85% of the patients, with a true error rate of 19% (95% confidence interval [CI], 8%-32%). The 3 nearest neighbors classifiers allowed a correct classification in 88% of the samples, with a true error rate of 16% (95% CI, 5%-28%).
RELATIONSHIP CIRCULATING MARKERS AND AKI
ET-1 and IL18 serum levels were significantly higher at each postoperative time point in the AKI group compared with the non-AKI group (Fig. 1 ). TNF-a levels after reperfusion and on POD 1 were significantly higher in the AKI group compared with the non-AKI (P 5 0.045). There was no significant correlation between ET-1 and the IL18 serum level and preoperative creatinine. The corresponding differences in the levels of the other cytokines were not significant. The maximum percent decrease of eGFR correlated significantly with ET-1 levels after reperfusion (r, 0.670; P < 0.001), POD 1 (r, 0.53; P < 0.0001), POD 2 (r, 0.67; P < 0.001), POD 5 (r, 0.48; P < 0.0001), and POD 7 (r, 0.45; P < 0.001). Correlation between maximum percent decrease of eGFR and ET-1 levels on POD 1 and POD 7 is shown in Fig. 2 . The maximum percent decrease of eGFR correlated significantly with IL18 levels after reperfusion (r, 0.27; P 5 0.024), POD 1 (r, 0.59; P < 0.001), POD 2 (r, 0.796; P < 0.001), POD 5 (r, 0.73; P < 0.001), and POD 7 (r, 0.73; P < 0.001). Correlation between maximum percent decrease of eGFR and IL18 levels on POD 1 and POD 7 is shown in Fig. 2 .
The area under the receiver operating characteristic curve (AUROC) for predicting AKI based on the day 1 serum level of ET-1 concentration was 0.84 (95% CI, 0.73-0.95). A cutoff level of 24 pg/mL was predictive of AKI with a sensitivity of 0.85 and specificity of 0.86. The AUROC for predicting AKI based on day 1 serum level of IL18 concentration was 0.83 (95% CI, 0.68-0.98). It was found that a cutoff level of 479 pg/ mL was predictive of AKI with a sensitivity of 0.80 and a specificity of 0.93. The AUROC for predicting AKI based on TNF-a concentration was 0.71 (95% CI, 0.64-0.81).
FIG. 1. (A) ET-1 and (B)
IL18 levels before LT, after reperfusion, and on PODs 1, 2, 5, and 7 in patients with AKI versus non-AKI, mean 6 SD. *P < 0.05; **P < 0.0001.
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ET-1, IL18, and TNF-a were considered in combination. The ROC curve for the best combinations of biomarkers was for POD 1 level of ET-11IL18 (AUROC, 0.91; 95% CI, 0.83-0.99). Figure 3 shows the ROC curve analysis for prediction of AKI by the POD 1 level of ET-1, IL18, and the combined ET-11 IL18. Table 3 compares POD 1 levels of ET-1, IL18, and TNF-a with other biomarkers of liver injury/prognosis on POD 1 with regard to our primary endpoint of AKI.
VARIABLES ASSOCIATED WITH POSTOPERATIVE AKI
Variables associated with perioperative AKI on univariate analysis are outlined in 
OUTCOME
Hospital and intensive care unit (ICU) stays were significantly longer in patients experiencing AKI (Table 1) . Graft and patient survival at 1 year after LT was lower in recipients with AKI, but this difference was not significant. In the AKI group, the percent decrease of eGFR within 12 months was significantly higher (P 5 0.002) than the patients who did not develop AKI (Fig.  4) . Recipients who experienced AKI after transplantation more frequently developed CKD stage 2 or higher compared with the non-AKI group (Table 1) .
Discussion
Early AKI injury after LT is thought to be multifactorial. Risk factors such as intrinsic CKD, intraoperative hemodynamic instability, infection, and operative time have been associated with early AKI after LT. (6, 10) Clinical studies have reported that recipients of marginal and donation after circulatory death (DCD) grafts, which are known to be more susceptible to IRI, have a higher incidence of AKI. (2, 11, 12) Leithead et al. have reported that peak AST is independently associated with the development of AKI. (4) Altogether these studies suggest that IRI is a main factor in determining renal impairment after LT. However, little is known about the mediators responsible for AKI following hepatic IRI.
In this prospective study, we demonstrated that early postreperfusion gene expression is a main determinant of new-onset AKI after LT. Several stressinduced cytokines, vascular mediators, adhesion molecules, and apoptotic cell death mediators were significantly more expressed in the AKI group compared with the non-AKI group. The increased expression of IRI genes in the AKI group is confirmed by the increased postoperative serum level of TNF-a, IL18, and ET-1 compared with the non-AKI group. The increased expression of proinflammatory mediators such as TNF-a, IL18, and ET-1 is responsible for the activation of other major downstream cytokines and immune cell pathways, which are known to affect graft injury and to extend beyond the hepatic allograft. (13) Logistic regression analysis shows that ET-1 and IL18 levels were independently associated with AKI. We have previously demonstrated that ET-1 serum levels correlate with hepatic microcirculation dysfunction after reperfusion in LT. (14) In addition to its role in IRI of the liver, ET-1 is also an important mediator of renal physiology. (15) Experimental studies have shown that ET-1 causes marked and prolonged renal vasoconstriction, manifested by profound reduction in renal blood flow and glomerular filtration rate. (15, 16) Furthermore, the kidney appears to be more sensitive to exogenous ET-1 compared with all other organs. (17) In humans, there is growing evidence that the ET-1 system is activated early following acute injury, (18) including LT. (14) Early studies have suggested the potential association between AKI and ET-1 after LT but were limited by small samples sizes. (19) (20) (21) Also, different definitions of AKI have been used. Our results showed that patients with AKI had significantly higher serum levels of ET-1 compared with patients without AKI. We also demonstrated that ET-1 levels were correlated with a decline in eGFR.
The most compelling evidence demonstrating the importance of the ET-1 system in AKI comes from experimental studies with endothelin receptor antagonists (ETRAs). In animal models of IRI, the administration of ETRAs had beneficial effects on hepatic microcirculation, attenuating histological damage and improving graft function. investigated a rat model of acute liver failure, which shared some of the hallmarks of hepatorenal syndrome. (27) In this study, the development of renal failure was prevented by ETRAs. (27) A growing number of experimental and preclinical studies suggested a potential clinical application of ETRAs in patients with renal disease including kidney transplantation. (16, 28) Blocking the ET pathway by selective ETRA antagonists has been associated with reduced short-term and longterm deterioration in kidney function. (16, 28) Furthermore, it has been hypothesized that treatment with ETRAs may ameliorate calcineurin inhibitor-mediated complications after solid organ transplantation. (28) IL18 is a novel biomarker that has been studied in detail in renal ischemia/reperfusion models, and it has been demonstrated to mediate renal tubular injury. (29, 30) IL18 is involved in the IRI of both kidneys and liver by activating activator protein 1 and nuclear factor kappa B and subsequently regulating the expression of other proinflammatory molecules. (31, 32) Previous studies have shown that IL18 levels are associated with AKI (33, 34) ; however, no study has established the liver as the main source of IL18. In this study, we demonstrated that hepatic IL18 gene expression is up-regulated early after reperfusion. Furthermore, we found that serum levels of IL18 were an independent predictor of the renal function deterioration after LT. Strategies targeting IL18, such as IL18 binding protein or neutralizing antibodies, have been demonstrated to improve renal function in experimental models of renal and hepatic IRI. (31, 32, 35) Current clinical trials are evaluating the use of IL18 binding protein as well as neutralizing antibodies to IL18 in treating several human diseases including AKI. (36) Postreperfusion syndrome and hemodynamic instability have been associated with the development of AKI after LT. (1, 37) However, similarly to other studies, (38, 39) we did not find a significant difference in postreperfusion syndrome and hemodynamic instability between the AKI and non-AKI groups. Furthermore, despite previous studies suggesting that peak transaminases are an independent predictor of AKI after LT, (4, 38) our study suggests that the ET-1 and IL18 serum levels outperform peak ALT for prognostic determination of AKI after LT.
Identifying an early predictive marker for AKI after LT could result in earlier treatment strategies to limit associated morbidity. Serum creatinine is not a reliable early marker of AKI because significant changes in creatinine concentration occur only after a significant amount of renal damage has occurred. (40) In patients at risk of AKI, but without an increase in serum creatinine, nephrotoxic medications and hypovolemia should be avoided, and closer monitoring and earlier use of RRT could be considered. In this study, we have demonstrated that both ET-1 and IL18 and their combination are more sensible and specific in determining patients at risk of AKI compared with classic biochemical tests.
Although it is thought that the injured liver is the main source of ET-1 and IL18, the kidney itself could also be an important source. However, this study demonstrated that patients who developed AKI had significantly higher hepatic expression of ET-1 and IL18 compared with patients who did not develop AKI. This suggests that the liver itself is the main source of ET-1 and IL18. As a result, strategies that minimize IRI have the potential to reduce AKI after LT.
In our study, those patients who developed AKI, renal function did not completely recover and were still impaired after 1 year. Similar findings were described by previous studies. (2, 41) In a large series, Wadei et al. described early postoperative renal failure after LT as a potential risk for developing chronic renal failure, which was associated with inferior longterm survival. (2) The current study is not without limitations. Obviously, this descriptive study is exploratory in nature. Consequently, it is not possible to define the mechanisms responsible of our results. Although the hepatic gene expression analysis suggested that the injured liver is a significant source of serum mediators responsible of AKI, the kidney itself could also be an important source of ET-1 and IL18. Because this study did not measure urine biomarkers, a possible renal source cannot be excluded. Unlike previous studies, our results did not confirm an increased frequency of AKI in DCD liver transplant recipients. (12) However, the limited number of DCD patients in this study does not allow drawing any firm conclusion.
In conclusion, we have demonstrated in a clinical setting that early postreperfusion gene expression is a main determinant of AKI after LT. ET-1 and IL18 may serve as potential clinical biomarkers for the prediction or early detection of AKI and are also promising pharmacological targets. It is of clinical interest that ET-1 receptor antagonist has been successfully introduced into the clinical practice for the treatment of pulmonary hypertension, and IL18 binding protein has been used safely in clinical trials of connective tissue disease. (28, 36) Our results suggest that the intrahepatic inflammatory response, rather than intraoperative hemodynamic instability, plays a main role in AKI after LT. Assessment of the serum level of IL18 and ET-1 could be used to identify patients at risk of AKI who may benefit from targeted pharmacological treatment.
